Explorative study on the use of omalizumab in patients suffering from interstitial cystitis/bladder pain syndrome

Daniele Porru, Enrica Bucchioni, Marcello Macchi, Fabio Leva, Alberto Parmigiani, Davide Barletta, Dimitrios Choussos, Barbara Gardella, Maria Diletta Daccò, Rossella Elena Nappi, Massimo Allegri, Carlo Maria Bianchi, Arsenio Spinillo, Bruno Rovereto

Research output: Contribution to journalArticlepeer-review


The aim of this study was to evaluate the efficacy of omalizumab in the treatment of Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS), evaluated by visual analogue score for pain and urgency- frequency, O'Leary-Sant IC symptom and problem index questionnaire, Pain Urgency Frequency questionnaire and Patient Global Assessment questionnaire. Four female patients with a diagnosis of IC/BPS were included in the study, with an age between 20 and 39 years. In the first patient the subjective final evaluation was of a marked improvement. The second patient had a moderate improvement of the subjective final evaluation. The third patient considered her overall clinical situation to have slightly improved after treatment. One 32-year-old patient, with multiple allergies, discontinued treatment after 3 months and could not complete the study due to side effects. Omalizumab was subcutaneously administered to patients with IC/PBS; it induced both a subjective and objective improvement of symptoms in 2 patients enrolled in the study.

Original languageEnglish
Pages (from-to)22-25
Number of pages4
JournalUrogynaecologia International Journal
Issue number1
Publication statusPublished - 2012


  • Anti-IgE treatment
  • Interstitial cystitis/bladder pain syndrome
  • Omalizumab

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Urology


Dive into the research topics of 'Explorative study on the use of omalizumab in patients suffering from interstitial cystitis/bladder pain syndrome'. Together they form a unique fingerprint.

Cite this